| Revision as of 22:40, 15 January 2016 editOsamaK (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers19,183 editsNo edit summary← Previous edit | Latest revision as of 16:31, 31 August 2021 edit undoRandey1970 (talk | contribs)Extended confirmed users14,225 editsNo edit summary | ||
| (3 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
| {{CatDiffuse}} | {{CatDiffuse}} | ||
| {{Commons category}} | |||
| {{Commonscat|Cancer treatment}} | |||
| {{Cat main|Treatment of cancer}} | |||
| ] | ] | ||
| ] | ] | ||
| {{CatAutoTOC}} | |||
Latest revision as of 16:31, 31 August 2021
 | Pages in this category should be moved to subcategories where applicable. This category may require frequent maintenance to avoid becoming too large. It should directly contain very few, if any, pages and should mainly contain subcategories. |
Contents
Subcategories
This category has the following 13 subcategories, out of 13 total.
A
- Alternative cancer treatments (1 C, 81 P)
- Antineoplastic drugs (17 C, 215 P)
C
- Cancer hormone therapy (1 P)
- Cereblon E3 ligase modulators (7 P)
- Chemotherapy (4 C, 36 P)
- Combination cancer drugs (12 P)
E
- Experimental cancer treatments (2 C, 34 P)
I
- Cancer immunotherapy (1 C, 19 P)
O
- Oncothermia (6 P)
R
- Radiation therapy (3 C, 68 P)
S
- Surgical oncology (65 P)
T
- Targeted therapy (7 P)
V
- Cancer vaccines (28 P)
Pages in category "Cancer treatments"
The following 113 pages are in this category, out of 113 total. This list may not reflect recent changes.
*
A
- Abscopal effect
- Active surveillance of low-risk papillary thyroid microcarcinoma
- Active surveillance of prostate cancer
- Adjuvant therapy
- ALECSAT
- Alternating electric field therapy
- Anti-malignin antibody
- Anti-VEGF
- Autogene cevumeran
- Autologous immune enhancement therapy
- Autologous patient-specific tumor antigen response
- Axicabtagene ciloleucel
B
C
- Cancer Drugs Fund
- Cancer pharmacogenomics
- Cancer rehabilitation
- Carmustine
- Chemosensitivity assay
- Chemotherapy
- Cisplatin
- Cobimetinib
- CXCR4 antagonist
- Cytarabine
- Cytokine-induced killer cell
D
E
F
- Fedratinib
- FLASH Radiotherapy
- Focused ultrasound for intracranial drug delivery
- Fruquintinib
- Functional Assessment of Cancer Therapy - General
G
H
- High-dose chemotherapy and bone marrow transplant
- HER2
- William Henry Hosking
- Host response to cancer therapy
I
L
- Lasers in cancer treatment
- Lifileucel
- Linear particle accelerator
- Lisocabtagene maraleucel
- Lomustine
- Lymphatogenous metastasis
M
N
- Nadofaragene firadenovec
- Neoadjuvant therapy
- NeuVax
- NGR-hTNF (antitumor recombinant protein)
- Nigro protocol
- Niraparib/abiraterone acetate
- Nitrogen mustard
- NK-92
O
P
- Panobinostat
- Peptide receptor radionuclide therapy
- Percutaneous hepatic perfusion
- PH-responsive tumor-targeted drug delivery
- PHEC-66
- Photodynamic therapy
- Photostatin
- Plasmonic nanoparticles
- Predictive marker
- Prehabilitation
- Procarbazine
- Prophylactic cranial irradiation
- Management of prostate cancer
R
S
T
- Tabelecleucel
- Tagraxofusp
- Targeted alpha-particle therapy
- Targeted therapy of lung cancer
- Tazemetostat
- Temozolomide
- Thiotepa
- Tislelizumab
- Tivozanib
- Trametinib
- Treatment of lung cancer
- Tucatinib
- Tumor board review
- Tumour heterogeneity